Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Consolidated Statements of Loss and Comprehensive Loss

v3.8.0.1
Consolidated Statements of Loss and Comprehensive Loss
shares in Thousands, $ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
shares
Dec. 31, 2016
CAD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2015
CAD ($)
$ / shares
shares
Statement Line Items [Line Items]          
Revenue
Expenses:          
Research and development (notes 11) 6,274 7,834 10,322 4,865 6,254
General and administrative (note 12) 5,552 6,439 8,344 7,992 9,845
Operating Expenses 11,826 14,273 18,666 12,857 16,099
Finance expense (note 13) 46 66 34 43
Finance income (note 13) (165) (79) (105) (1,180) (1,516)
Net finance income (165) (33) (39) (1,146) (1,473)
Net loss for the year (11,661) (14,240) (18,627) (11,711) (14,626)
Other comprehensive loss          
Translation adjustment 485 (3,519)
Comprehensive loss for the year $ (11,661) $ (13,755) $ (18,627) $ (15,230) $ (14,626)
Basic and diluted loss per common share (in dollars per share) | (per share) $ (0.52) $ (1.12) $ (1.46) $ (0.98) $ (1.23)
Weighted average number of common shares outstanding used in the calculation of (in thousands) (note 9(e)): Basic and diluted loss per common share (in shares) 22,313 12,743 12,743 11,906 11,906